Stock Traders Buy Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw some unusual options trading activity on Wednesday. Investors purchased 1,002 put options on the stock. Thisisanincreaseof1,791% compared to the typical daily volume of 53 put options.

Maravai LifeSciences Trading Down 12.8%

MRVI opened at $2.04 on Thursday. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $9.95. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.96 and a quick ratio of 5.17. The firm has a market capitalization of $519.51 million, a price-to-earnings ratio of -1.79 and a beta of 0.28. The company’s 50 day moving average price is $2.40 and its two-hundred day moving average price is $2.74.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Maravai LifeSciences had a negative net margin of 67.14% and a negative return on equity of 12.91%. The firm had revenue of $46.85 million during the quarter, compared to the consensus estimate of $44.01 million. The firm’s quarterly revenue was down 26.9% on a year-over-year basis. As a group, research analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRVI has been the topic of several research reports. Robert W. Baird decreased their price target on shares of Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. Craig Hallum decreased their price target on shares of Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Maravai LifeSciences presently has an average rating of “Hold” and an average target price of $6.64.

Institutional Investors Weigh In On Maravai LifeSciences

Institutional investors have recently modified their holdings of the company. Callan Family Office LLC bought a new stake in shares of Maravai LifeSciences in the 2nd quarter valued at $25,000. Ethic Inc. bought a new stake in shares of Maravai LifeSciences in the 2nd quarter valued at $26,000. McAdam LLC bought a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $31,000. Sherbrooke Park Advisers LLC acquired a new position in shares of Maravai LifeSciences during the 4th quarter valued at $78,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Maravai LifeSciences during the 1st quarter valued at $32,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.